Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies

Group 1: Collaboration and Strategy - Amgen Inc. is collaborating with Ro, a telehealth firm, to investigate barriers patients face in accessing obesity treatments, particularly GLP-1 drugs [2][3] - The collaboration aims to leverage data from Ro's platform to assess insurance coverage, prior authorization requirements, and improve patient access to GLP-1 therapies [3] - Amgen expects the observational research from this collaboration to aid in therapy development and innovate care delivery [3] Group 2: Acquisition and Oncology Focus - Amgen acquired Dark Blue Therapeutics for up to $840 million, a UK-based biotech company focused on small molecule protein degraders for acute myeloid leukemia [4] - The acquisition supports Amgen's strategy to enhance early oncology discovery and commitment to novel therapeutic mechanisms [4] Group 3: Company Overview - Amgen Inc. is a biotechnology company that develops, manufactures, and markets human therapeutics, founded in 1980 and headquartered in Thousand Oaks, CA [5]